Skip to main content

Health condition

Morphea, a localised scleroderma that behaves very differently from the systemic disease.

Patches of hardened, thickened skin that can look alarming - but morphea does not typically involve internal organs, and with the right treatment ladder it usually settles well.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Editorial team

    Written by our editorial team from the UK sources listed on each page.

  • 02

    Sourced from guidance

    Checked against British Association of Dermatologists (BAD) guidance and peer-reviewed sources you can see at the end.

  • 03

    Current for 2026

    Reflects modern UK dermatology and rheumatology practice, including methotrexate use and paediatric monitoring for linear disease.

Key facts

Morphea at a glance.

The essentials, in plain English - what it is, how it differs from systemic scleroderma, and how it’s treated in the UK today.

  • What it is

    A localised form of scleroderma - patches of thickened, hardened skin, sometimes involving deeper tissue. It is not the same disease as systemic sclerosis.

  • Not systemic

    Morphea does not typically affect internal organs and generally carries a much better prognosis than systemic scleroderma.

  • Main subtypes

    Plaque, linear, generalised and deep morphea - each with a different distribution and level of functional risk.

  • Two disease phases

    An active, inflammatory phase with violaceous borders, followed by a sclerotic phase of hardened, ivory-coloured skin.

  • Linear morphea in children

    Can cross joints or growth plates, risking contractures or limb length discrepancy - needs early, dedicated attention.

  • First-line systemic treatment

    Methotrexate, often with an initial course of corticosteroids, for extensive, linear or deep disease.

Why this guide matters

The name causes more worry than the disease usually warrants.

"Scleroderma" is a frightening word to hear. These three points are the ones that matter most once morphea is confirmed.

  • It is not systemic sclerosis

    Morphea stays confined to the skin and, sometimes, the tissue just beneath it - internal organ involvement is not a typical feature.

  • Subtype changes the plan

    A single plaque on the trunk is managed very differently from linear disease crossing a joint or affecting the face.

  • Timing of treatment matters

    Treating active disease early - especially linear or deep subtypes - limits the damage that is much harder to reverse later.

How the diagnosis is made

From first patch to a confirmed plan.

The steps a UK dermatologist, and where needed a rheumatologist, will normally follow, in order - so you know what to expect and why.

  1. 01

    Assessing

    Clinical examination

    Characteristic appearance and distribution of plaques, assessing whether disease is active (inflammatory) or inactive (sclerotic, atrophic).

  2. 02

    Assessing

    Skin biopsy if uncertain

    Confirms the diagnosis histologically, showing dermal thickening and collagen changes - read by specialist dermatopathology.

  3. 03

    Confirming

    Joint and limb assessment

    Clinical assessment of joint range of motion where linear morphea crosses a joint, and limb length checks in growing children.

  4. 04

    Confirming

    Imaging for deep disease

    MRI, used selectively, to assess the extent of subcutaneous fat, fascial or muscle involvement in deep morphea.

  5. 05

    Confirming

    Scleroderma antibody testing

    Selective testing to help exclude systemic sclerosis where there is diagnostic uncertainty or overlapping features - morphea itself lacks the typical systemic sclerosis antibody profile.

  6. 06

    Preparing

    Paediatric growth assessment

    Ongoing limb length monitoring and orthopaedic input where linear morphea affects a growing limb.

  7. 07

    Preparing

    Dermatology and rheumatology MDT

    Joint specialist input, particularly for linear or deep subtypes with functional implications.

Typical timeline: assessment and a first treatment plan within a few weeks, with follow-up over months.

Symptoms

What morphea actually looks like.

The subtypes range from a single quiet plaque to widespread or deep disease. And the features that mean it’s time to escalate.

  • Plaque morphea

    The most common form - oval or round hardened patches, often with a violaceous border when active and an ivory, waxy centre as it progresses. Typically on the trunk.

  • Linear morphea

    Band-like lesions, more common in children. Can cross joints, causing contractures, or affect the limb growth plates.

  • "En coup de sabre"

    Linear morphea affecting the frontal scalp or forehead - can be associated with underlying tissue atrophy, including facial hemiatrophy in rare Parry-Romberg overlap.

  • Generalised morphea

    Multiple widespread plaques with more extensive skin involvement, needing a broader systemic treatment approach.

  • Deep morphea

    Involves deeper tissue - subcutaneous fat, fascia and sometimes muscle - with greater functional impact than superficial plaques.

  • Active versus sclerotic phase

    Erythematous or violaceous plaques in the active phase, progressing to hardened, shiny, hyper- or hypopigmented skin as disease becomes inactive.

  • Joint contractures

    Linear or deep morphea crossing a joint can restrict movement over time if not treated and monitored with physiotherapy.

  • Red flag - facial or scalp involvement

    Linear disease on the face or scalp warrants prompt specialist review given the risk of cosmetic and functional impact.

Treatment

How morphea is treated in the UK.

Topical measures and phototherapy for limited plaque disease, methotrexate for more extensive, linear or deep morphea, and physiotherapy wherever a joint is involved.

  • Topical corticosteroids

    Potent topical steroids for limited, superficial plaque morphea, particularly during the active inflammatory phase.

  • Topical calcineurin inhibitors

    Tacrolimus ointment as a steroid-sparing option for limited plaque disease.

  • Phototherapy

    UVA1 or narrowband UVB, effective for more widespread superficial plaque morphea, helping to soften affected skin.

  • Methotrexate

    First-line systemic treatment for extensive, linear or deep morphea, often combined with an initial course of corticosteroids.

  • Physiotherapy

    Essential where linear morphea crosses a joint, to maintain range of motion and prevent or manage contractures.

  • Surgical or reconstructive input

    Selective, for significant cosmetic deformity or contracture once disease is inactive - for example fat grafting or contracture release.

  • Orthopaedic monitoring

    In children with linear morphea affecting a limb, watching for limb length discrepancy and managing it where significant.

  • Psychological support

    Given the visible skin changes, particularly with facial involvement, support for body image and quality of life matters.

What this guide is based on

The sources behind every claim on this page.

UK national guidance and specialist society standards, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your dermatologist or rheumatologist knows your skin, subtype and history and can tell you which parts apply to you. If in doubt, get seen.

  • British Association of Dermatologists (BAD). Guidance on morphea (localised scleroderma).

  • British Society for Paediatric and Adolescent Rheumatology. Juvenile localised scleroderma guidance.

  • Scleroderma and Raynaud’s UK. Patient information on morphea and localised scleroderma.

  • European Dermatology Forum. Guideline on the diagnosis and treatment of sclerosing skin diseases.

Red flags

When morphea needs urgent attention.

Most plaque morphea is manageable at a steady pace. These are the situations that need earlier or more intensive specialist input.

  • Linear morphea crossing a joint

    Risk of progressive contracture and functional limitation - needs early physiotherapy and systemic treatment, not a watch-and-wait approach.

  • Facial or scalp linear disease

    "En coup de sabre" can progress to facial asymmetry or atrophy - warrants prompt dermatology and, where relevant, plastic surgery input.

  • Limb length discrepancy in children

    Linear morphea crossing a growth plate needs orthopaedic monitoring to catch and manage any growth disturbance early.

  • Rapidly progressive or widespread plaques

    Fast-spreading generalised morphea should prompt earlier escalation to systemic treatment rather than topical measures alone.

  • Features suggesting systemic sclerosis

    Raynaud’s phenomenon, nailfold capillary changes, or internal organ symptoms are not typical of morphea and need urgent rheumatology assessment to exclude systemic sclerosis.

  • Deep morphea with muscle involvement

    Involvement of fascia or muscle causes greater functional impact and usually needs earlier, more intensive systemic treatment.

  • Significant psychological impact

    Visible facial or widespread skin change can affect body image and mental health significantly - deserves proactive psychological support.

  • Diagnostic uncertainty

    Where the distinction between morphea and systemic sclerosis is unclear, a skin biopsy and antibody testing help clarify the diagnosis and guide care.

Living with it

A condition that runs a slow course, with a clear ladder.

Four things that make the biggest difference day to day - understanding what morphea is not, keeping joints moving, tracking change over months, and asking for support with how it looks.

A quiet reminder

Slow and steady is normal here, not a sign treatment isn’t working.

Morphea can stay active for a long time before settling - regular follow-up, not urgency, is usually the right rhythm.

  1. 01 Understand

    Know it is not systemic sclerosis

    Morphea generally has a much better prognosis and does not typically involve internal organs - reassurance matters alongside treatment.

  2. 02 Move

    Keep joints moving

    If a patch crosses a joint, regular physiotherapy exercises help prevent stiffness and contracture over time.

  3. 03 Track

    Watch the skin over months, not days

    Morphea can remain active for years before settling - photographs and regular follow-up help track whether it is improving.

  4. 04 Support

    Ask for help with how it looks

    Facial or visible involvement can be difficult - psychological support and, later, reconstructive options are both reasonable to ask about.

Frequently asked

Everything we get asked about morphea.

Quick answers on subtypes, systemic sclerosis, children, and treatment with methotrexate and phototherapy.

  • What is morphea?

    Morphea, also called localised scleroderma, is a condition causing patches of thickened, hardened skin and sometimes deeper tissue. It is distinct from systemic sclerosis (systemic scleroderma) because it does not typically involve internal organs and generally has a much better outlook.

  • Is morphea the same as systemic scleroderma?

    No. Morphea is a localised skin condition, while systemic sclerosis can affect internal organs such as the lungs, heart and gut. Morphea does not usually show the specific antibody profile seen in systemic sclerosis, though testing is sometimes used to rule this out if there is uncertainty.

  • What are the main types of morphea?

    Plaque morphea (the most common, causing oval hardened patches), linear morphea (band-like lesions, more common in children, which can cross joints or affect the scalp and face), generalised morphea (widespread plaques) and deep morphea (involving fat, fascia or muscle).

  • Can morphea affect children?

    Yes, particularly linear morphea. In children it can cross growth plates and cause limb length discrepancy, so orthopaedic monitoring alongside dermatology and rheumatology care is important.

  • How is morphea treated?

    Limited plaque disease often responds to topical corticosteroids, topical tacrolimus or phototherapy. More extensive, linear or deep morphea usually needs methotrexate, sometimes alongside an initial course of oral corticosteroids, plus physiotherapy if a joint is affected.

  • Does morphea ever go away?

    Morphea can remain active for months or years before eventually becoming quiescent (burnt out). Treatment aims to control activity and limit damage while it runs its course, and surgical or cosmetic options are considered once the disease is inactive.

Related content

Keep reading.